TMEM9B

Across TCGA pan-cancer cohorts, TMEM9B mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TMEM9B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TMEM9B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types TMEM9B is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

CCRCC, PDAC, and LSCC are the cancer types where TMEM9B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TMEM9B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	−0.652	<.001	12	view →
PDAC	Female	II,III,IV	+0.812	<.001	6	view →
LSCC	Male	II,III,IV	−0.260	<.001	6	view →
COAD	Female	III,IV	−0.431	.026	4	view →
LUAD	All	II,III,IV	+0.146	.010	2	view →
HNSC	Male	III,IV	−0.147	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TMEM9B–CCRCC

Open the CCRCC breakdown →